Dicerna Pharmaceuticals (OTCMKTS:SLNCF) was the target of a large increase in short interest in August. As of August 31st, there was short interest totalling 3,800 shares, an increase of 52.0% from the August 15th total of 2,500 shares. Based on an average daily volume of 900 shares, the short-interest ratio is currently 4.2 days.

Separately, HC Wainwright assumed coverage on Dicerna Pharmaceuticals in a research note on Monday, August 24th. They issued a “buy” rating on the stock.

Shares of OTCMKTS:SLNCF opened at $6.14 on Wednesday. Dicerna Pharmaceuticals has a 52-week low of $2.08 and a 52-week high of $7.70.

About Dicerna Pharmaceuticals

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs.

Recommended Story: What is a Tariff?

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.